TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27651510

Group type: EXPERIMENTAL
Intervention: Manipulated high-volume morphine-ADER-IMT (60 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Manipulated low-volume morphine-ADER-IMT (60 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intact oral morphine-ADER-IMT (60 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Manipulated low-volume morphine ER (60 mg)
Number of subjects: 46
Study: 27655459

Group type: EXPERIMENTAL
Intervention: Sleep education (3 messages: bedtime before 21:00; no caffeine; keep electronics out of the bedroom)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control (dental hygiene education)
Number of subjects: 152
Study: 22740112

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 21993207

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 74
Study: 19436225

Group type: EXPERIMENTAL
Intervention: 0.5% DHEA
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 0.25% DHEA
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 1.0% DHEA
Number of subjects: 216
Study: 17589628

Group type: EXPERIMENTAL
Intervention: Surgical revascularization
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 483

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 483
Study: 14987957

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) intervention, 10 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison experience
Number of subjects: 29
Study: 11342682

Group type: EXPERIMENTAL
Intervention: lamotrigine (150 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: carbamazepine (mean 696 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: nondrug average
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: lamotrigine
Number of subjects: 25
Study: 9683389

Group type: EXPERIMENTAL
Intervention: Reduced fat products
Number of subjects: 241

Group type: COMPARATOR
Intervention: Full fat products
Number of subjects: 241
Study: 8149032

Group type: EXPERIMENTAL
Intervention: 5 milligrams per kilogram per minute of glucose infusion during preoperative overnight fasting
Number of subjects: 12

Group type: COMPARATOR
Intervention: No infusion (control group) during preoperative overnight fasting
Number of subjects: 12
Study: 2980998

Group type: EXPERIMENTAL
Intervention: Peritoneoscopy with directed liver biopsy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Blind percutaneous liver biopsy
Number of subjects: 23
Study: 31385712

Group type: EXPERIMENTAL
Intervention: Conversational valence
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Conversational valence with popular conversation partner
Number of subjects: 112
Study: 31209507

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28173786

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Peer Support
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control
Number of subjects: 124
Study: 25782429

Group type: EXPERIMENTAL
Intervention: Vegetarians
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Daily fruit consumption
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Topical fluoride application
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nonvegetarians
Number of subjects: 200
Study: 23996803

Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol per day for 3 months
Number of subjects: 35
Study: 21873902

Group type: EXPERIMENTAL
Intervention: Push-ups with feet elevated on a 30.48-cm box
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Push-ups with hands elevated on a 30.48-cm box
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Push-ups from the flexed knee position
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Push-ups with hands elevated on a 60.96-cm box
Number of subjects: 23
Study: 19470837

Group type: EXPERIMENTAL
Intervention: Active pramlintide
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo pramlintide
Number of subjects: 266
Study: 17878479

Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg plus docetaxel
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg plus docetaxel
Number of subjects: 127

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 127
Study: 15135147

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (1500 mg daily for 12 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (1500 mg daily for 12 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate and Placebo
Number of subjects: 19
Study: 10690829

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin‐C (0.3 mg/ml) applied under both flaps (group 3)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin‐C (0.3 mg/ml) applied under the scleral flap (group 2)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin‐C (0.3 mg/ml) applied under the conjunctival flap (group 1)
Number of subjects: 68
Study: 9368726

Group type: EXPERIMENTAL
Intervention: Simultaneous chemotherapy with radiotherapy
Number of subjects: 19
Study: 8461475

Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 3771854

Group type: EXPERIMENTAL
Intervention: Topical tretinoin in combination with 0.5% minoxidil
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Topical tretinoin alone
Number of subjects: 56
Study: 29980818

Group type: EXPERIMENTAL
Intervention: Cannabis decoction (200 ml)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cannabis oil (1 ml)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cannabis decoction and cannabis oil
Number of subjects: 13
Study: 27720409

Group type: EXPERIMENTAL
Intervention: 24-hour recall conditions (two retention intervals: short and long; four prompts: forward, meal name, open, and reverse)
Number of subjects: 455
Study: 24996447

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) administered one pill a day for 63 days
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) plus Dan'e mixture (30 g/day for 30 days)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Laparoscopy alone (Control Group C)
Number of subjects: 156
Study: 22799753

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment administered twice daily for 52 weeks
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 504
Study: 20141396

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 56

Group type: COMPARATOR
Intervention: Citalopram/Escitalopram
Number of subjects: 56

Group type: COMPARATOR
Intervention: No antidepressant
Number of subjects: 56
Study: 18031326

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 1 mg/m²/day for 12 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-GH treated control group
Number of subjects: 43
Study: 15695835

Group type: EXPERIMENTAL
Intervention: Periwound cleansing using a skin cleanser
Number of subjects: 17
Study: 14508234

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lisinopril 20 mg
Number of subjects: 32
Study: 10834421

Group type: EXPERIMENTAL
Intervention: lispro high mixture (HM)
Number of subjects: 35

Group type: COMPARATOR
Intervention: human regular insulin therapy
Number of subjects: 35
Study: 8807200

Group type: EXPERIMENTAL
Intervention: MN rgp120 HIV-1 vaccine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IIIB rgp120 HIV-1 vaccine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Priming immunization with IIIB rgp120 followed by booster injections of MN rgp120
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MN rgp120 HIV-1 vaccine given alone
Number of subjects: 25

Group type: COMPARATOR
Intervention: HIV-1IIIB-based gp160 vaccines
Number of subjects: 25
Study: 1555315

Group type: EXPERIMENTAL
Intervention: Not applicable (no intervention mentioned)
Number of subjects: 40
Study: 4029016

Group type: EXPERIMENTAL
Intervention: Temocillin 250 mg/h
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Temocillin 750 mg/h
Number of subjects: 5

Group type: COMPARATOR
Intervention: Probenecid (blocking tubular excretion)
Number of subjects: 5
Study: 29058272

Group type: EXPERIMENTAL
Intervention: Health blog
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control blog
Number of subjects: 0
Study: 28353022

Group type: EXPERIMENTAL
Intervention: 0.2% morphine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.4% morphine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (0.2% morphine, 0.4% morphine, placebo)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 26221049

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 32
Study: 24645871

Group type: EXPERIMENTAL
Intervention: Short-term integrative body-mind training (IBMT) for 30 min per day for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Relaxation training (RT)
Number of subjects: 40
Study: 22456699

Group type: EXPERIMENTAL
Intervention: Usual practice dysphagia therapy
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Survey responses from SLPs
Number of subjects: 759
Study: 19843655

Group type: EXPERIMENTAL
Intervention: Perphenazine (8 to 32 mg daily for 14 to 600 days)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Perphenazine in nonsmoking African Americans
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Perphenazine in nonsmoking other races
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Perphenazine in active smokers
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Perphenazine in smoking African Americans
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Perphenazine in smokers of other races
Number of subjects: 156
Study: 17506736

Group type: COMPARATOR
Intervention: Bupivacaine alone (1 ml of 0.25% bupivacaine on each side)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bupivacaine with pethidine (1 ml of 0.25% bupivacaine and 0.25 mg.kg(‐1) body weight pethidine)
Number of subjects: 40
Study: 15652871

Group type: EXPERIMENTAL
Intervention: Nocturnal urinary excretion of 6‐sulphatoxymelatonin in patients with autism
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normal control individuals (matched on age, sex, and Tanner stage)
Number of subjects: 49
Study: 11308250

Group type: EXPERIMENTAL
Intervention: DTIC (850 mg/m² every 28 days) plus IFN-alpha2a/b (3 MIU/m², twice on day 1, once daily from days 2 to 5; 5 MIU/m² 3 times a week from week 2 to 4)
Number of subjects: 290

Group type: COMPARATOR
Intervention: DTIC (850 mg/m² every 28 days) plus IFN-alpha2a/b (3 MIU/m², twice on day 1, once daily from days 2 to 5; 5 MIU/m² 3 times a week from week 2 to 4) plus IL-2 (4.5 MIU/m² for 3 hours i.v. on day 3; 9.0 MIU/m² i.v. day 3/4; 4.5 MIU/m² s.c. days 4 to 7)
Number of subjects: 290
Study: 9447531

Group type: EXPERIMENTAL
Intervention: Surfactant dosing through a proximal sideport adapter
Number of subjects: 36

Group type: COMPARATOR
Intervention: Surfactant dosing through a double-lumen endotracheal tube
Number of subjects: 36
Study: 7543288

Group type: EXPERIMENTAL
Intervention: 153Sm‐EDTMP (330 MBq to 1110 MBq)
Number of subjects: 35
Study: 3065744

Group type: EXPERIMENTAL
Intervention: alpha 2b Interferon
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (non-treated)
Number of subjects: 34
Study: 2405806

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine treatment combined with intensive group psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment combined with intensive group psychotherapy
Number of subjects: 0
Study: 339672

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Diphenoxylate
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 30824256

Group type: EXPERIMENTAL
Intervention: TAU+APP (treatment as usual with app access)
Number of subjects: 129

Group type: COMPARATOR
Intervention: TAU (treatment as usual without app access)
Number of subjects: 129
Study: 27805273

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bipolar radiofrequency combined with diode laser (BRDL)
Number of subjects: 24
Study: 25494297

Group type: EXPERIMENTAL
Intervention: Low-iodine-load protocol (400 mg iodine per kg at 80 kVp)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Moderate-iodine-load protocol (400 mg iodine per kg at 80 kVp)
Number of subjects: 113

Group type: COMPARATOR
Intervention: High-iodine-load protocol (600 mg iodine per kg at 120 kVp)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Low-iodine-load protocol
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Moderate-iodine-load protocol
Number of subjects: 113
Study: 23274606

Group type: EXPERIMENTAL
Intervention: PACER test
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treadmill GXT
Number of subjects: 45
Study: 21299845

Group type: EXPERIMENTAL
Intervention: Intravenous darbepoetin infusion and intracoronary infusion of peripheral blood stem cells mobilized with G‐CSF (n = 58)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of peripheral blood stem cells mobilized with G‐CSF alone (n = 29)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional therapy (n = 29)
Number of subjects: 116
Study: 19741605

Group type: EXPERIMENTAL
Intervention: native E. coli asparaginase
Number of subjects: 40

Group type: COMPARATOR
Intervention: PEG asparaginase
Number of subjects: 40
Study: 16758918

Group type: EXPERIMENTAL
Intervention: Chronopuncture as a non-drug method of arterial pressure correction
Number of subjects: 0
Study: 14691440

Group type: EXPERIMENTAL
Intervention: Carvedilol treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard therapy (placebo group)
Number of subjects: 27
Study: 11340718

Group type: EXPERIMENTAL
Intervention: Fluoride mouthrinse
Number of subjects: 414

Group type: COMPARATOR
Intervention: No mouthrinse
Number of subjects: 414
Study: 9154757

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 15 micrograms acetylcholine chloride
Number of subjects: 29
Study: 7957035

Group type: EXPERIMENTAL
Intervention: Vigabatrin (1.5 g twice daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vigabatrin (continued for at least 35 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 45
Study: 3331395

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.36 mg/kg/day for 9 days (group S)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (group NS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexamethasone (group S)
Number of subjects: 24
Study: 28560756

Group type: EXPERIMENTAL
Intervention: Nursing care plan applied using NANDA, NOC, and NIC linkages for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific intervention not mentioned)
Number of subjects: 0
Study: 28448225

Group type: EXPERIMENTAL
Intervention: Positive Thinking Training (PTT) online intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25559324

Group type: COMPARATOR
Intervention: PegIFN/RBV plus placebo (arm 1)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: PegIFN/RBV plus faldaprevir (120 mg, once daily for 12 or 24 weeks) (arm 2)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: PegIFN/RBV plus faldaprevir (240 mg, once daily for 12 weeks) (arm 3)
Number of subjects: 652
Study: 23007137

Group type: EXPERIMENTAL
Intervention: Active stretching program (12 weeks, 3 days/week, 180 seconds daily)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 138
Study: 20655261

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 2831

Group type: COMPARATOR
Intervention: MenACWY-D
Number of subjects: 2831

Group type: COMPARATOR
Intervention: MPSV4
Number of subjects: 2831
Study: 19205171

Group type: EXPERIMENTAL
Intervention: Low-level laser stimulation treatment (5 mV, 650 nm, 20 minutes daily for 3 months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46
Study: 17190951

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 0
Study: 14598939

Group type: EXPERIMENTAL
Intervention: ST regimen (streptomycin 1 g/day i.m. for 15 days and tetracycline‐HCl 500 mg every 6 h orally for 45 days)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SD regimen (streptomycin 1 g/day i.m. for 15 days and doxycycline 100 mg every 12 h orally for 45 days)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: DR regimen (doxycycline 100 mg every 12 h orally for 45 days and rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: OR regimen (ofloxacin 200 mg every 12 h orally for 45 days and rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SDR regimen (streptomycin 1 g/day i.m. for 15 days and doxycycline 100 mg every 12 h orally for 45 days plus rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Number of subjects: 102
Study: 11379605

Group type: EXPERIMENTAL
Intervention: Low dose interferon (3 MU day‐1, twice weekly for 6 months)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 95
Study: 9231885

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (a nitric oxide donor) during experimentally induced migraine crisis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (a nitric oxide donor) during spontaneous migraine attack
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control groups (healthy subjects and episodic tension headache patients)
Number of subjects: 50
Study: 7911286

Group type: EXPERIMENTAL
Intervention: acrivastine (8 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: terfenadine (120 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 3074300

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 30
Study: 31627907

Group type: EXPERIMENTAL
Intervention: Dual-tracer (isotopic and dye) technique for sentinel lymph node identification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sentinel lymph node identification
Number of subjects: 0
Study: 31345792

Group type: EXPERIMENTAL
Intervention: G-CSF-mobilized blood stem cell (G-PB) grafts
Number of subjects: 410

Group type: COMPARATOR
Intervention: Bone marrow (BM) grafts
Number of subjects: 410
Study: 28050795

Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rigid cystoscopy
Number of subjects: 100
Study: 26266385

Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation (APC) along with distilled water injection
Number of subjects: 116

Group type: COMPARATOR
Intervention: Distilled water injection alone
Number of subjects: 116
Study: 22806264

Group type: EXPERIMENTAL
Intervention: Mini-subvastus approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard medial parapatellar approach
Number of subjects: 40
Study: 21810044

Group type: EXPERIMENTAL
Intervention: Single dose of 500 mg PLC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single dose of 1000 mg PLC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiple doses of 500 mg PLC twice a day over 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiple doses of 1000 mg PLC twice a day over 7 days
Number of subjects: 24
Study: 19654097

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued medical management (proton pump inhibitors)
Number of subjects: 0
Study: 17116604

Group type: EXPERIMENTAL
Intervention: < 25% expected injury guidance
Number of subjects: 2610

Group type: EXPERIMENTAL
Intervention: 25%-49% expected injury guidance
Number of subjects: 2610
Study: 15599861

Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy and chemotherapy (RT-CT) - 226 patients; 70 Gy in 35 fractions with three cycles of a 4-day regimen comprising carboplatin and 5-fluorouracil (5FU)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (RT) - 268 patients; 64 Gy in 3 weeks
Number of subjects: 494

Group type: COMPARATOR
Intervention: Conventional radiotherapy (RT) - 70 Gy in 35 fractions
Number of subjects: 494
Study: 10669274

Group type: COMPARATOR
Intervention: General anaesthesia followed by an infusion of normal saline (Control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia with continuous epidural infusion of 2% lidocaine (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: General anaesthesia with K+M+B administered 10 min after 2% lidocaine injection and 30 min before skin incision (Group III)
Number of subjects: 60
Study: 8659355

Group type: EXPERIMENTAL
Intervention: Primary signs
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Secondary signs
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both primary and secondary signs
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Secondary signs (specific signs identified)
Number of subjects: 74
Study: 1307517

Group type: EXPERIMENTAL
Intervention: Inhaled aerosol of platelet activating factor (PAF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpheniramine
Number of subjects: 0
Study: 3834227

Group type: EXPERIMENTAL
Intervention: Cuprophane (CUP) membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyacrilonitrile (PAN) membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro treatment with CUP membrane fragments
Number of subjects: 0